{"disease":{"id":"prevention-of-motion-sickness","name":"Prevention of Motion Sickness","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"meclizine","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclizine","company_name":"Generic (originally Pfizer/UCB)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor","drug_class":"Antihistamine/Antiemetic (vestibular suppressant)","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"meclozine","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antivert","generic_name":"meclozine","company_name":"Citron Pharma Llc","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"Antiemetic","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dimenhydrinate","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimenhydrinate","generic_name":"DIMENHYDRINATE","company_name":"Alra","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dimenhydrinate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Prevention of Motion Sickness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}